Hogan Lovells (Washington)

Jonathan Elsasser

Hogan Lovells (Washington)
Lawyer (Associate)

Jonathan Elsasser helps health care and life sciences companies navigate complex antitrust and health regulatory issues and achieve their business goals. Jonathan has extensive experience at all phases of the merger review process and has represented clients on matters before the Federal Trade Commission, U.S. Department of Justice, and several state attorneys general. While Jonathan has worked with clients in a variety of industries, he has significant experience representing health care and life sciences companies, including hospitals and health systems, payers, health technology companies, medical supply distributors, medical device manufacturers, and pharmaceutical companies. Jonathan has advised clients on a wide range of transaction-related issues, including assessments of proposed transactions or collaborations, Hart-Scott-Rodino filings, government investigations, and information sharing and integration planning. Jonathan also regularly advises clients on regulatory issues related to sales strategies, strategic initiatives, the fraud and abuse laws, and compliance policies and procedures. He is a member of the American Bar Association (ABA) Antitrust Section and the American Health Lawyers Association. Prior to law school, Jonathan worked as a paralegal on antitrust, environmental, and litigation matters at a Washington, D.C., law firm.

Linked authors

Hogan Lovells (Milan)
University of Oxford
Hogan Lovells (London)
Hogan Lovells (London)
Hogan Lovells (Brussels)


264 Bulletin

Bob Leibenluft, Leigh L. Oliver, Jonathan Elsasser The US FTC initiates proceedings against two hospitals to prevent their proposed merger (Hackensack Meridian Health / Englewood Healthcare)


On 4 August 2021, the District Court of New Jersey granted the Federal Trade Commission’s (FTC) motion for preliminary injunction, preventing Hackensack Meridian Health (HMH) and Englewood Healthcare (Englewood) from closing their proposed merger pending an administrative trial before an FTC (...)

Send a message